BioStock Intestor Meeting: Interview with Redwood Pharma
Stockholmbased Redwood Pharma participated in the BioStock Investor Meeting in September where CEO Martin Vidaeus presented the company’s work. Afterwards, BioStock had the chance to interview Vidaeus who told us more about Redwood Pharma’s projects RP501 and RP101, aimed at the treatment of dry eyes.
See the interview with Redwood Pharma’s CEO Martin Vidaeus below.
Please note that the interview was recorded before the news that Redwood Pharma’s board of directors has resolved on a share issue of approximately 33,2 MSEK.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.